Design Therapeutics (DSGN) Total Current Liabilities (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Total Current Liabilities of $11.2 million for Q2 2026, up 28.5% year-over-year from $8.7 million in Q2 2025, and up 10.3% on a QoQ basis from $10.2 million in Q1 2026.
Design Therapeutics (DSGN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $11.2 million in Q2 2026.
- Total Current Liabilities for Q2 2026 came in at $11.2 million, up 28.5% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.2 million (up 28.5% YoY), and the FY2025 annual result was $13.1 million, up 54.28% from the prior year.
- Total Current Liabilities rose to $11.2 million in Q2 2026, from $10.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $13.1 million in Q4 2025 and troughed at $5.5 million in Q1 2022.
- A 5-year average of $9.4 million and a median of $9.3 million in 2023 frame the typical range for Total Current Liabilities.
- The widest annual swing landed in 2022, when Total Current Liabilities surged 116.98%; it then tumbled 47.3% in 2024.
- A 5-year view of Total Current Liabilities shows it stood at $10.8 million in 2022, then declined by 10.71% to $9.6 million in 2023, then dropped by 12.06% to $8.5 million in 2024, then soared by 54.28% to $13.1 million in 2025, then fell by 13.9% to $11.2 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $11.2 million in Q2 2026, $10.2 million in Q1 2026, and $13.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | 11.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.24 Mn |
| Mar 31, 2026 | 10.19 Mn |
| Dec 31, 2025 | 13.06 Mn |
| Sep 30, 2025 | 11.17 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 8.24 Mn |
| Dec 31, 2024 | 8.46 Mn |
| Sep 30, 2024 | 7.43 Mn |
| Jun 30, 2024 | 6.39 Mn |
| Mar 31, 2024 | 7.09 Mn |
| Dec 31, 2023 | 9.62 Mn |
| Sep 30, 2023 | 12.39 Mn |
| Jun 30, 2023 | 12.13 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | 10.78 Mn |
| Sep 30, 2022 | 10.41 Mn |
| Jun 30, 2022 | 7.39 Mn |
| Mar 31, 2022 | 5.48 Mn |
| Dec 31, 2021 | 5.28 Mn |
| Sep 30, 2021 | 5.51 Mn |